CagrilintidevsSemaglutide

Cagrilintide is a long-acting analogue of amylin, a 37-amino-acid peptide hormone naturally co-secreted with insulin from pancreatic beta cells after meals. Native amylin plays a crucial but often overlooked role in metabolic regulation — it signals satiety, slows gastric emptying, and suppresses post-meal glucagon secretion through mechanisms entirely distinct from the GLP-1 pathway.

Cagrilintide activates amylin receptors, which are heterodimeric complexes formed by the calcitonin receptor (CTR) paired with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). These receptors are concentrated in the area postrema and the nucleus tractus solitarius in the brainstem — regions outside the blood-brain barrier that can directly sense circulating peptides. Activation of these neurons triggers ascending satiety signals to the hypothalamus, reducing meal size and food-seeking behavior through pathways that are neuroanatomically separate from GLP-1 signaling.

This distinct mechanism is why cagrilintide produces additive appetite suppression when combined with semaglutide (as CagriSema) — the two peptides target different populations of neurons within the brain's appetite control circuitry. Cagrilintide has been engineered with acylation modifications that enable albumin binding, extending its half-life from minutes (native amylin) to approximately one week, making it suitable for weekly subcutaneous dosing.

Semaglutide is a modified version of the natural incretin hormone GLP-1, engineered with 94% structural homology to the native peptide. It binds to GLP-1 receptors expressed throughout the body, triggering a cascade of metabolic effects. In the pancreas, it stimulates glucose-dependent insulin secretion from beta cells while suppressing glucagon release from alpha cells, providing dual glycemic control that only activates when blood sugar is elevated.

In the central nervous system, semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamic arcuate nucleus and the brainstem's nucleus tractus solitarius. This suppresses appetite by modulating POMC/CART (anorexigenic) and NPY/AgRP (orexigenic) neuronal pathways. The result is a significant reduction in hunger, food cravings, and caloric intake — patients typically experience a fundamental shift in their relationship with food.

The extended duration of action comes from a C18 fatty di-acid chain attached at position 26 (lysine), which enables strong non-covalent binding to circulating albumin. This albumin binding shields semaglutide from DPP-4 enzymatic degradation — the process that destroys native GLP-1 within minutes — extending its half-life to approximately 7 days. Additionally, semaglutide slows gastric emptying through vagal nerve signaling, contributing to post-meal satiety and reduced glycemic excursions.